期刊文献+

结直肠癌肝转移手术治疗123例疗效分析 被引量:11

Effect of surgical treatment on colorectal cancer with liver metastasis an analysis of 123 patients
原文传递
导出
摘要 目的探讨影响结直肠癌肝转移手术治疗的预后因素。方法回顾性分析中国医学科学院肿瘤医院腹部外科2000年1月至2011年1月资料完整并行手术治疗的123例结直肠癌肝转移病人的临床资料。结果全组病人1,3,5年存活率分别为87.2%,35.6%及21.1%。单因素分析显示肿瘤大小、术前癌胚抗原(CEA)水平、是否R0切除是影响预后的因素(P<0.05)。COX多因素分析显示是否R0切除是影响预后的独立危险因素。结论手术切除是结直肠癌肝转移病人获得长期生存的最佳手段,综合治疗是病人达到R0切除、改善远期疗效的关键。 Objective To explore the prognostic risk factors for colorectal cancer patients with liver metastasis who received surgical treatment. Methods The clinieopathological characters of 123 eolorectal cancer with liver metastasis patients who received surgical treatment between January 2000 and January 2011 in Cancer Hospital of CAMS were analyzed retrospectively. Results In all patients, 1,3,5-year survival were 87.2%, 35.6% and 21.1% respectively. Univariate analysis showed size of liver tumor, level of preoperative CEA, R0 resection were risk factors for prognosis. Multivariate analysis showed that R0 resection was the only independent risk factor. Conclusion Surgical treatment is still the optimal modality for coloreeta] cancer with liver metastasis. R0 resection is the key point for the patients to get a better prognosis.
出处 《中国实用外科杂志》 CSCD 北大核心 2012年第2期133-135,144,共4页 Chinese Journal of Practical Surgery
关键词 结直肠癌 肝转移 肝切除 colorectal cancer liver metastasis hepatectomy
  • 相关文献

参考文献9

  • 1Pawlik TM, Schlick RD, Choti MA. Expanding criteria for resect- ability of colorectal liver metastases [J]. Oncologist,2008,13(1): 51-64.
  • 2Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic coloreetal metastases [J]. Ann Surg, 2002, 235(6):759-766.
  • 3Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies [J ]. Br J Cancer, 2006, 94 (7): 982-999.
  • 4刘凯,李哲,段纪成,黄耀,杨家和,沈锋,吴孟超.结肠癌伴肝转移同期切除影响预后相关因素分析[J].中国实用外科杂志,2009,29(8):662-664. 被引量:4
  • 5张海增,董淑晓,周志祥,赵平,邵永孚.结直肠癌同时性肝转移的同期手术切除[J].中华外科杂志,2007,45(13):902-904. 被引量:1
  • 6Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorec- tal resections are safe for synchronous colorectal liver metastasis [J].J Am Coil Surg, 2003,197(2) : 233-241.
  • 7Are C, Gonen M, Zazzali K, et al. The impact of margins on out- come after hepatic resection for colorectal metastasis [J]. Ann Surg, 2007, 246(2):295-300.
  • 8Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase 11 tri- al of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colnrectal cancer[Jl. J Clin Oncol,2007,25(33) : 5225-5232.
  • 9陆明,沈琳.结直肠癌肝转移新辅助化疗的相关问题分析[J].中国实用外科杂志,2009,29(1):26-29. 被引量:7

二级参考文献40

  • 1樊嘉,王征.大肠癌同时性肝转移的治疗[J].中国实用外科杂志,2005,25(8):460-462. 被引量:7
  • 2Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: Acontraindication to liver resection for multiple colorectal metastases? [J]. Ann Surg, 2004,240(6): 1052-1061.
  • 3Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver melastases after chemotherapy: Does it mean cure? [J]. J Clin Oncol,2006, 24(24):3939-3945.
  • 4Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinicacid and oxaliplatin in patients with primary respectable liver metastases of colorectal cancer [J]. Oncology, 2003, 64 (2): 131-138.
  • 5Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: Results for a phase Ⅱ study[J]. J Clin Oncol, 2005,23:502-509.
  • 6Nordlinger B, Sorbye H, Glimelius B,et al.Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Inter group trial 40983): a randomised controlled trial [J].Lancet, 2008,371 (9617): 1007-1016.
  • 7Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with Cetuximab/FOLFOX-4 in the treatment of mCRC epidermal growth factor receptor expressing metastatic colorectal carcinoma [J]. Ann Oncol,2006, 17: 450-456.
  • 8Petters M, Raoul JL, van Laethem JL, et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid(FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC) [ J ]. Euro J Cancer,2005,17 (suppl 3 ): 188.
  • 9Koehne C, Zaluski J, Chung Rong C, et al. Cetuximab plus FOLFIRI first-line in metastatic colorectal cancer (mCRC): the randomized phase Ⅲ CRYSTAL trial [J]. Ann Oncol ,2007,18 (suppl 7): 21.
  • 10Min BS, Kim NK, Ahn JB, et al. Cetuximab in Combination with 5-Fluorouracil, Leucovorin and Irinotecan as a Neoadjuvent Chemotherapy in Patients with Initially Unresectable Colorectal Liver Metastases [J ]. Onkologie, 2007,(12): 637-643.

共引文献9

同被引文献85

引证文献11

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部